中国药物警戒 ›› 2013, Vol. 10 ›› Issue (4): 235-237.

• 药械安全性研究 • 上一篇    下一篇

63例奥沙利铂联合氟尿嘧啶/甲酰四氢叶酸治疗结直肠癌的不良反应分析

李志义1,骆玉霜2*   

  1. 1.青海省药品不良反应监测中心,青海西宁810007；
    2.青海大学附属医院,青海西宁810001
  • 收稿日期:2013-02-21 修回日期:2016-03-09 出版日期:2013-04-08 发布日期:2016-03-09
  • 通讯作者: 骆玉霜,女,临床医学,副主任医师。 E-mail:qfyluoyushuang@163.com
  • 作者简介:李志义,男,主治医师,药品不良反应监测与评价。

Analysis of 63 Cases of ADR Caused by Capecitabine Platinum Joint Fluorouracil/leucovor in Treatment of Colorectal Cancer

LI Zhi -yi1 ,LUO Yu -shuang2   

  1. 1.Qinghai Province Adverse Drug Reaction Monitoring Center, Qinghai Xining 810001 China;
    2.Qinghai University Medical School, Qinghai, Xining 810001 China
  • Received:2013-02-21 Revised:2016-03-09 Online:2013-04-08 Published:2016-03-09

PDF (PC)

234

摘要： 目的 探讨奥沙利铂联合氟尿嘧啶（5-Fu）/ 甲酰四氢叶酸治疗结直肠癌致不良反应的规律和原因,为临床合理用药提供参考。方法 对2007 年～2012 年青海大学附属医院63 例采用奥沙利铂联合5-Fu/ 甲酰四氢叶酸治疗结直肠癌所致不良反应病例报告进行分析,分别从患者性别、年龄、用药剂量、累及系统- 器官及临床表现等方面进行统计、分析。结果 63 份不良反应病例报告中,40～60 岁的患者不良反应发生率最高,共计39 例,占61.90％；不良反应最为常见的临床表现为神经系统损害（占44.44%）,其次为消化系统系统（占29.63%）以及血液系统（占17.78%）损害。结论 FOLFOX 方案治疗结直肠癌所致不良反应的发生与药物因素有关,并且年龄分布特点符合该方案的适应人群。应加强医务人员对FOLFOX 方案治疗恶性肿瘤致不良反应的上报意识,分析不良反应的发生特点,促进临床用药安全。

关键词: 奥沙利铂联合5-Fu/甲酰四氢叶酸, 结直肠癌, 药品不良反应

Abstract: Objective Through analysing 63 ADR cases of the capecitabine platinum joint Fluorouracil/leucovor in treatment of colorectal cancer, to explore the rules and causes of adverse reactions, provide a reference for clinical rational use of drugs. Methods Analyzed 63 ADR cases caused by capecitabine platinum joint fluorouracil/leucovor in treatment of colorectal cancer in terms of gender, age, drug dose, organ or system involved and clinical manifestation, which were searched from 2007～2012 at the Affiliated Hospital of Qinghai University. Results Patients at the age of forty to sixty were with the highest incidence of ADR,a total of 39 cases, accounting for 61.90% . The most common clinical manifestations of ADR was nervous system damage(44.44%), followed by the digestive system(29.63%) and blood system (17.78%) damage. Conclusion The occurrence of ADR caused by FOLFOX scheme colorectal cancer treatment was related to drug factors, and age distribution characteristics accorded with the adaptation crowd. The medical professionals should raise the awareness of reporting ADR induced by FOLFOX scheme in the treatment of malignant tumor. It needs to analyze the characteristics of the ADR occurrence to ensure the clinical drug use safety.

Key words: capecitabine platinum joint fluorouracil/leucovor, colorectal cancer, adverse drug reaction(ADR)

中图分类号: